PL2249842T3 - Zastosowanie 25-hydroksy-witaminy D3 i witaminy D do oddziaływania na fizjologię ludzkich mięśni - Google Patents

Zastosowanie 25-hydroksy-witaminy D3 i witaminy D do oddziaływania na fizjologię ludzkich mięśni

Info

Publication number
PL2249842T3
PL2249842T3 PL09710537T PL09710537T PL2249842T3 PL 2249842 T3 PL2249842 T3 PL 2249842T3 PL 09710537 T PL09710537 T PL 09710537T PL 09710537 T PL09710537 T PL 09710537T PL 2249842 T3 PL2249842 T3 PL 2249842T3
Authority
PL
Poland
Prior art keywords
vitamin
hydroxy
human muscle
affect human
muscle physiology
Prior art date
Application number
PL09710537T
Other languages
English (en)
Inventor
Neil Robert Buck
Wouter Claerhout
Bruno H. Leuenberger
Elisabeth Stoecklin
Kai Urban
Swen Wolfram
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40551381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2249842(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of PL2249842T3 publication Critical patent/PL2249842T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • A23L33/155Vitamins A or D
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL09710537T 2008-02-13 2009-02-12 Zastosowanie 25-hydroksy-witaminy D3 i witaminy D do oddziaływania na fizjologię ludzkich mięśni PL2249842T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2851008P 2008-02-13 2008-02-13
US3167108P 2008-02-26 2008-02-26
US3692408P 2008-03-14 2008-03-14
US3692808P 2008-03-15 2008-03-15
US12913908P 2008-06-06 2008-06-06

Publications (1)

Publication Number Publication Date
PL2249842T3 true PL2249842T3 (pl) 2017-01-31

Family

ID=40551381

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09710537T PL2249842T3 (pl) 2008-02-13 2009-02-12 Zastosowanie 25-hydroksy-witaminy D3 i witaminy D do oddziaływania na fizjologię ludzkich mięśni

Country Status (13)

Country Link
US (3) US20110039810A1 (pl)
EP (1) EP2249842B1 (pl)
JP (1) JP5593550B2 (pl)
KR (1) KR101561717B1 (pl)
CN (2) CN101951916A (pl)
AU (1) AU2009214054B2 (pl)
BR (1) BRPI0907953A2 (pl)
EA (1) EA019837B1 (pl)
ES (1) ES2599761T3 (pl)
IL (1) IL207588A (pl)
MX (1) MX2010008904A (pl)
PL (1) PL2249842T3 (pl)
WO (1) WO2009101137A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3095447T3 (da) 2006-02-03 2022-01-31 Opko Renal Llc Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
PL2481400T3 (pl) 2007-04-25 2015-04-30 Opko Ip Holdings Ii Inc Sposoby i kompozycje dawki doustnej do kontrolowanego uwalniania związku będącego witaminą D
EP3225243A1 (en) 2007-04-25 2017-10-04 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
US20110039810A1 (en) 2008-02-13 2011-02-17 Neil Robert Buck Use of 25-hydroxy-vitamin d3 to affect human muscle physiology
ES2954932T3 (es) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados
EP2321273B1 (en) * 2008-07-24 2014-11-19 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
CN105796530A (zh) 2010-03-29 2016-07-27 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
US9707242B2 (en) * 2013-03-27 2017-07-18 Dsm Ip Assets B.V. Use of 25-hydroxyvitamin D3 to enhance executive functions
EP3193925A2 (en) 2014-08-07 2017-07-26 OPKO Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d
MX2018011820A (es) 2016-03-28 2019-01-24 Opko Ireland Global Holdings Ltd Metodos de tratamiento con vitamina d.
CN108902985A (zh) * 2018-06-08 2018-11-30 唐飞 25-羟基维生素d3在制备保健食品中的应用
IT202100007655A1 (it) * 2021-03-29 2022-09-29 Abiogen Pharma Spa Uso di colecalciferolo come coadiuvante nel trattamento di distrofie muscolari
CN114128763B (zh) * 2021-11-24 2024-02-27 北大荒完达山乳业股份有限公司 一种维生素d3营养强化剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020037279A1 (en) * 1996-09-13 2002-03-28 Herman H. Vandenburgh Delivery of bioactive compounds to an organism
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
WO2005027650A1 (en) * 2003-09-22 2005-03-31 Dsm Ip Assets B.V. Vitamin containing pet food compositions
US7212141B2 (en) * 2005-07-11 2007-05-01 Intel Corporation Filter with gain
EP1945185B1 (en) * 2005-10-12 2016-02-03 Proventiv Therapeutics, LLC Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
ATE476104T1 (de) * 2005-11-25 2010-08-15 Dsm Ip Assets Bv Verwendung von 25-hydroxy-vitamin d3 zur verbesserung der vitalität von tieren
DK3095447T3 (da) * 2006-02-03 2022-01-31 Opko Renal Llc Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3
PL2481400T3 (pl) * 2007-04-25 2015-04-30 Opko Ip Holdings Ii Inc Sposoby i kompozycje dawki doustnej do kontrolowanego uwalniania związku będącego witaminą D
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
US20110039810A1 (en) 2008-02-13 2011-02-17 Neil Robert Buck Use of 25-hydroxy-vitamin d3 to affect human muscle physiology
US8772230B2 (en) * 2009-06-11 2014-07-08 Dsm Ip Assets B.V. Niacin and/or trigonelline as a muscle stimulant
US8168611B1 (en) * 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation

Also Published As

Publication number Publication date
CN101951916A (zh) 2011-01-19
KR20100117113A (ko) 2010-11-02
EP2249842A1 (en) 2010-11-17
EA201001285A1 (ru) 2011-02-28
KR101561717B1 (ko) 2015-10-19
CN107412237A (zh) 2017-12-01
ES2599761T3 (es) 2017-02-03
EP2249842B1 (en) 2016-07-27
EA019837B1 (ru) 2014-06-30
MX2010008904A (es) 2010-11-05
US20160263128A1 (en) 2016-09-15
IL207588A (en) 2016-06-30
BRPI0907953A2 (pt) 2015-08-04
WO2009101137A1 (en) 2009-08-20
IL207588A0 (en) 2010-12-30
JP5593550B2 (ja) 2014-09-24
JP2011511828A (ja) 2011-04-14
US20110039810A1 (en) 2011-02-17
US20130150598A1 (en) 2013-06-13
AU2009214054B2 (en) 2014-12-18
AU2009214054A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
PL2249842T3 (pl) Zastosowanie 25-hydroksy-witaminy D3 i witaminy D do oddziaływania na fizjologię ludzkich mięśni
HK1212210A1 (en) Combined use of 25-hydroxy-vitamin d3 and vitamin d3 d3 25-- d3
HK1199828A1 (en) Compositions and methods for stimulating magp-1 to improve the appearance of skin magp-1
EP2611413A4 (en) SKIN COMPOSITIONS AND THEIR APPLICATIONS
HK1173654A1 (zh) 治療化合物及相關的使用方法
HK1215281A1 (zh) 人骨骼肌中的褐色脂肪細胞祖細胞
EP2448581A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF
EP2219600A4 (en) TOPICAL COSMETIC SKIN COMPOSITIONS AND APPLICATION METHOD THEREFOR
HK1187345A1 (en) Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
EP2432492A4 (en) APPLICATION AND USE OF PRG4 AND THERAPEUTIC MODULATION THEREOF
EP2461691A4 (en) THERAPEUTIC VITAMIN D SUNSCREEN FORMULATIONS AND METHOD OF USE THEREOF
EP2238969A4 (en) PREPARATION FOR EXTERNAL APPLICATION TO THE SKIN AND COSMETIC PREPARATION
IL207589A0 (en) Combination of vitamin d and 25-hydroxyvitamin d3
EP2170404A4 (en) COMPOSITIONS WITH HUMAN EGFR SIRNA AND METHOD OF USE
PT2549995T (pt) Utilização de anatabina para tratar inflamação e métodos de sintetizar a anatabina
PT2429502T (pt) Método e composição para melhorar a absorção de aspirina
EP2249826A4 (en) COMPOSITIONS AND METHODS OF USING COMPOUNDS TO EXTEND THE SURVIVAL PERIOD OF CANCER PATIENTS
IL211844A0 (en) Skin treatments containing carboxylic acid-substitiuted idebenone derivatives and methods of preparation and use thereof
EP2274325A4 (en) ANALOGUE OF HUMAN G-CSF AND METHOD OF MANUFACTURE AND APPLICATION THEREOF
EP2344191A4 (en) HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE
HK1116706A1 (en) One kind of external use chinese medicine which used to treat itchy skin disease
EP2509628A4 (en) SR-BI AS A PREDICTOR OF HUMAN FEMALE BARRENESS AND RESPONSE TO TREATMENT
PL2173356T5 (pl) Stosowanie 25-hydroksywitaminy d3 do zwiększania masy mięśniowej u ssaków
PT2461816E (pt) Utilização do xénon para tratar a hipersensibilidade à dor
IL214353A0 (en) Dimeric pyrrolopyrimidinedione and its use in therapy of respiratory diseases